Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, successfully passed resolutions at its 2024 Annual General Meeting. The company is advancing its lead asset, ATH434, in Phase 2 clinical trials targeting Multiple System Atrophy, while also expanding its drug discovery platform. Based in Melbourne and San Francisco, Alterity aims to revolutionize treatments for Parkinsonian disorders.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
